Share on StockTwits

ICON plc (NASDAQ:ICLR) was upgraded by stock analysts at DA Davidson from a “neutral” rating to an “outperform” rating in a report issued on Thursday, Analyst Ratings Network.com reports.

ICON plc (NASDAQ:ICLR) traded up 2.84% on Thursday, hitting $39.87. 1,246,568 shares of the company’s stock traded hands. ICON plc has a 52 week low of $31.74 and a 52 week high of $50.00. The stock has a 50-day moving average of $45.10 and a 200-day moving average of $42.47. The company has a market cap of $2.455 billion and a P/E ratio of 23.50.

ICON plc (NASDAQ:ICLR) last released its earnings data on Wednesday, April 30th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.07. The company had revenue of $350.00 million for the quarter, compared to the consensus estimate of $352.14 million. During the same quarter in the previous year, the company posted $0.36 earnings per share. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. Analysts expect that ICON plc will post $2.14 EPS for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at ISI Group cut their price target on shares of ICON plc from $56.00 to $50.00 in a research note on Wednesday. They now have a “strong-buy” rating on the stock. Separately, analysts at Zacks downgraded shares of ICON plc from an “outperform” rating to a “neutral” rating in a research note on Monday. They now have a $51.70 price target on the stock. Finally, analysts at Credit Suisse initiated coverage on shares of ICON plc in a research note on Thursday, March 27th. They set an “outperform” rating and a $55.00 price target on the stock. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $51.08.

ICON public limited company (NASDAQ:ICLR) is a contract research organization (CRO), providing outsourced development services on a global basis to the pharmaceutical, biotechnology and medical device industries.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.